Revolutionising healthcare with infant bacteria
We’re unlocking the potential of infant gut bacteria to combat diseases and extend lives.
Chronic diseases are responsible for 74% of all deaths worldwide.
“Traditional therapies are insufficient and often cause harmful side effects. Microbes hold the key to treating chronic diseases, but existing approaches to microbial drug development are flawed.”
We’re leading studies in infant bacteria
It all begins with immune system reprogramming
Infant bacteria play a crucial role in shaping and educating the immune system during early life, and the loss of these bacteria increases the likelihood of severe diseases.
We have the largest collection of infant bacteria in the world
Our database includes the most extensive and diverse collection of infant bacteria, providing unmatched resources for therapeutic development.
We use innovative methods to mine the life-changing compounds
We leverage a unique techniques and methodolody to extract and develop groundbreaking drugs from infant bacteria, addressing chronic diseases with innovative, effective therapies.
A unique approach to developing drugs from gut bacteria
Mechanism-first drug discovery
Our proprietary mechanism-first platform is designed to decode the precise mechanisms by which novel microbe-derived compounds exert their therapeutic effects at scale. Focussing on detailed mechanistic pathways ensures the development of highly targeted and effective therapies.
Exclusive infant bacteria strains
Our proprietary collection of unique infant bacteria is the largest in the world, and the source of our therapeutic compounds
Microorganism-derived active compounds
By focusing on microorganism-derived active compounds, we negate the potential complications often experienced while using live bacteria. This approach allows us to create therapies that offer unique advantages over traditional methods, addressing specific biological targets with superior effectiveness.
Our pioneering research and development
Learn more about the scientific process that helped create our lead candidate, BIOS-001. This drug has displayed dramatic efficacy in inhibiting breast tumour growth and enhancing responses to chemotherapy and immunotherapy.
Meet our co-founders
Meet the dedicated minds behind Bioscopic. Our core team and advisors bring unparalleled expertise and a shared vision to revolutionise healthcare through microbiome science.
Dr Chris Price CEO
An expert in microbial therapeutics and immuno-oncology, Chris is an expert in immunology, oncology, and microbiology. His extensive experience in developing foundational data and platforms drives our innovative vision.
Prof Lindsay Hall CTO
Lindsay is the Chair of Microbiome at the University of Birmingham and Group Leader at QIB, and is a world-leading expert on infant bacteria, host-microbe interactions, and multi-omic integration.
Dr Stephen Robinson CSO
A leader at Quadram Institute Bioscience (QIB) and Senior Lecturer at the University of East Anglia, Stephen has over 20 years of experience in cancer biology, focusing on pre-clinical models and molecular biology.
Contact us
Whether you’re a publisher looking to feature groundbreaking scientific advancements, an investor seeking innovative opportunities, or a professional ready to make a difference, we want to hear from you. Our doors are open for collaboration, partnership, and growth.
Email
invest@bioscopic.co
Media enquiries
media@bioscopic.co
Careers
work@bioscopic.co
Quadram Institute Research Park
Rosalind Franklin Rd, Norwich NR4 7UQ